Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US4327799	Helmholtz-Institut fur Biomedizinische Technik, DE	Yes			Process of freezing stem cells		stem cells			
US4411990	University Patents, Inc., Norwalk, CT	Yes			Growing and Assaying the stem cell content in a specimen	method for measuring drug sensitivity of the tumor stem cells of a specimen of primary explanted cells obtained from a primary or metastatic human tumor as an indication of the antineoplastic activity of a drug against said human tumor	cells obtained from primary or metastatic human tumors			
US4714680	The Johns Hopkins University, Baltimore, MD, US			Yes			lympho- hematopoietic stem cells of human	Blood or bone marrow		
US4812443	Kuraray Co., Ltd., Okayama, JP		Yes				hematopoietic progenitor cells		Yes	
US4904259	ITAY; SAMUEL, IL		Yes				autologous bone marrow stroma cells; autologous muscle fibroblast derived chrondocytes; bone marrow osteogenic- chondrogenic progenitor cells		regenerating skeletal tissue by implantation	

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5004681	Biocyte Corporation, New York, NY, US			Yes			neonatal or fetal hematopoietic stem cells	blood		
US5032507	The Salk Institute for Biological Studies. The Regents of the University of California Scripps Clinic and Research Foundation, San Diego, CA , Berkeley, CA , La Jolla, CA, US	Yes	Yes		culturing the cells to form erythroid colony-forming units		hematopoietic stem cells		To increase the population of erythrocytes in a human by injecting erythrocytes	
US5035994	The Johns Hopkins University, Baltimore, MD, US	Yes			Isolating human cells containing pluripotent lympho- hematopoie ic stem cells from mature human myeloid and lymphoid cells		lympho- hematopoietic stem cells	Marrow and blood		
US5041289	Becton Dickinson and Company, Franklin Lakes, NJ, US	Yes			Cytotoxic cells in an autologous cell preparation are activated in vitro with IL-2 and then combined with enriched progenitor cells.		human progenitor cells			
US5073481	Beth Israel Hospital Association, Boston, MA, US	Yes				Detecting presence of hep virus using stem cells	Stem cells from bone marrow and leukemic cell line	bone marrow of peripheral blood		

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5130144	The Johns Hopkins University, Baltimore, MD, US		Yes				human cells comprising pluripotent lympho- hematopoietic stem cells	Marrow or blood	to restore the production of lymphoid and hematopoietic cells in a patient where such production is lacking	
US5147784	SyStemix, Inc., Palo Alto, CA, US	Yes				Methodology is provided for identifying the presence of human T- lymphocyte progenitor cells	human progenitor cells			
US5147799	SPITALNY; GEORGE		Yes		Yes		hematopoietic stem cells			
US5149544	Research Corporation Technologies, Inc., Tucson, AZ, US	Yes					hematopoietic progenitor cell			
US5162215	Amgen Inc. Arbor Acres Farm, Inc., Thousand Oaks, CA Glastonbury, CT, US		Yes		Yes		EMBRYONIC			
US5175004	MATSUMURA; KENNETH N., US	Yes	Yes				progenitor cells		Cell replacement therapy	
US5175384	GenPharm International, Inc., Mountain View, CA, US		Yes			To make trangene offspring mouse by administering an embryonic stem cell containing the transgene into the embryo of the mouse.	cell			

Patent Number	Assignee/Applica nt Name	in vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5178856	Board of Regents of the University of Oklahoma, Norman, OK, US	Yes			Yes		megakaryocyte progenitor			
US5185323	Temple University, Philadelphia, PA, US		Yes				magakaryocyte progenitor cells		To treat thromboembolic disease or disorder by suppressing the maturation of immature magakaryocyte progenitor cells	
US5192553	Biocyte Corporation, New York, NY, US	Yes	Yes		Isolation and preservation of fetal and neonatal hematopoie ic stem and progenitor cells of he blood		fetal and neonatal hematopoietic stem and progenitor cells of the blood	Blood	method for hematopoietic or immune reconstitution of a human by introducing into the human a composition comprising human neonatal or fetal hematopoietic stem cells derived from the blood	
US5197985	HAYNESWORTH; STEPHEN E. US	Yes	Yes		mesenchymal stem cells that have been isolated, purified and culturally expanded from a bone marrow specimen, further differentiated into bone cells		mesenchymal stem cells	human marrow	Reparing skeletal defects or repairing damaged articular cartilage by implanting the porous carrier containing he mesenchymal stem cells into the defective skeletal tissue	

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5199942	Immunex Corporation, Seattle, WA, US		Yes				hematopoietic progenitor cells		autologous transplantation for cytoreductive therapy	
US5226914	HAYNESWORTH; STEPHEN E. US	yes					mesenchymal cells	human marrow- derived		Pros hetic device
US5229265	Litron Laboratories, Rochester, NY, US		yes			A flow cytometry process for determining changes, caused by chemical or biological agents, in blood or bone marrow cell popula ions	blood Stem cells	mice		
	CellPro Incorporated, Bothell, WA, US									A cell separator in combination with a column for collecting target cells from a sample fluid

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5252479	Research Corporation Technologies, Inc., Tucson, AZ, US					An expression vector for site- specific integration and cell-specific expression	a hematopoietic stem or progenitor cell.			
US5256534	The United States of America as represented by the Department of Health and Human Services, Washington, DC, US			A purified and isolated cell line which is derived from a hematopoietic cell and wherein the cells of said cell line are CD4.sup.+ and comprise a latent HIV-1 provirus.			hematopoietic cell			
US5256560	University of Saskatchewan, Saskatoon, CA			A suspension of mammalian, non- murine, non- human cells comprised of pluripotent lymphohematopoi etic non-adherent progenitor stem cells (NA cells) substantially free of mature lymphoid and myeloid cells and A suspension of pluripotent lymphohematopoi etic non-adherent progenitor stem cells (NA cells) derived from a human			pluripotent lymphohematopoi etic non-adherent progenitor stem cells	mammalian		

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5258367	University of Florida, Gainesville, FL, US		yes			A method of stimulating hematopoietic cells in an animal with a hematopoietic disorder				
US5300422	Case Western Reserve University, Cleveland, OH, US	yes				A method of determining patient sensitivity to N- desme hylclozapin e which comprises collecting heparinized blood from a patient, isolating CFU-GM, BFU-E and CFU- GEMM stem cells from said blood, subjecting said cells to a stem cell assay to determine the effect of N- desme hylclozapin e on the growth of said cells and A method of detec ing the onset of agranulocytosis complications in a patient on clozapine therapy		Blood or bone marrow		

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5308764	The United States of America as represented by the Administrator of the National Aeronau ics and Space Administration, Washington, DC, US			A multi-cellular, three-dimensional, differentiated, living mammalian tissue of at least two distinct originating cell types in which one cell type is fibroblasts and the other cell type is pluripotent human adenocarcinoma .			pluripotent xadenocarcinoma	human		
US5328695	Massachusetts Institute of Technology, Cambridge, MA, US	yes		comprising one or more water soluble proteins isolated from mammalian bone, wherein the	A method of inducing myogenesis n undifferentiated stem cells in culture or in a patient in need of treatment thereof		stem cell			

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5340740	North Carolina State University, Raleigh, NC, US	yes			A method of producing a sustained culture of undifferentiated avian cells expressing an embryonic stem cell phenotype		Embryonicstemcel	avian		
US5342776	BOLNET MARIE C N DIETERLEN LIEVRE FRANCOISE A	yes		essentially of			hemopoietic cells	avian		

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5354557	Stryker Corporation, Kalamazoo, MI, US						migratory progenitor cells	mammal		An osteogenic device for implantation in a mammal, the device comprising: osteogenic protein dispersed within a biocompatible, in vivo biodegradeable matrix defining pores of a dimension sufficient to permit influx, differentiation, and proliferation of migratory progenitor cells from the body of said mammal
022323046	Cell Genesys, Inc. The Regents of the University of California, Foster City, CA Oakland, CA, US			A hematopoietic stem cell comprising a DNA sequence encoding a membrane bond protein			nematopoietic stem cell			

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5362716	The United States of America as represented by the Department of Health and Human Services, Washington, DC, US		yes		A method of stimulating hematopoie ic progenitors comprising administering to mammals a hematopoie ic progenitor stimulating effective amount of Hepatocyte Grow h Factor and at least one other growth factor selected from the group consisting of IL-3 and GM- CSF.		hematopoietic progenitors	mammalian		
US5374658	Ortho Phamaceutical Corporation, Raritan, NJ, US		yes			A method for the selective suppression of at least one subpopulation of deleterious cells within a graft popula ion of mammalian cells	myeloid progenitor cells	mammalian		
US5397706	CORREA; PAULO N. ALEXRAD; ARTHUR A., CA/CA			A basal serum- free medium for maintaining cells selected from the group consisting of hematopoietic stem cells, hematopoietic progenitor cells and leukemia cells			hematopoietic stem cells, hematopoietic progenitor cells			

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5399493	The Regents of the University of Michigan, Ann Arbor, MI, US	yes			A method for obtaining ex vivo human hematopoie ic stem cell stable genetic transforma ion		hematopoietic stem cell	human		
US5405772	Amgen Inc., Thousand Oaks, CA, US			A medium for the long-term prolifera ion and development of cells			hematopoic ic progenitor cells			
US5409813	SyStemix, Inc., Palo Alto, CA, US	yes				A method for selectively separating at least one mammalian target cell popula ion from a suspension of a mixture of cell popula ions wherein the suspension contains he target cell population and at least one nontarget cell popula ion	progenitor cells	human		

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5411883	Somatix Therapy Corporation, Alameda, CA, US	yes		A culture consisting essentially of mammalian ventral mesencephalon neuron progenitor cells or mammalian ventral mesencephalon neuron progenitor cells and their differentiated counterparts	A method for producing a culture comprising neuron progenitor cells		ventral mesencephalon neuron progenitor cells or ventral mesencephalon neuron progenitor cells	mammalian		
US5416260	University of North Carolina at Chapel Hill, Chapel Hill, NC, US		yes	A genetically engineered mouse characterized by inactivation of the .betasub.2 - microglobulin gene and lacking functional Class I major histocompatibility complex antigens		A method of producing a genetically engineered mouse lacking functional Class I major histocompatibility complex antigens	embryonic stem cells	mouse		
US5434340	GenPharm International, Inc., Mountain View, CA, US		yes	A transgenic mouse		A method for producing a transgenic mouse	embryonic stem cell	mouse		

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5436151	Regents of the University of Minnesota, Minneapolis, MN, US	yes			cell culture method comprising culturing in vitro a population of hematopoie ic human stem cells supported in a non- contacting relationship to a supported population of cultured stromal cells		hematopoietic stem cells	human		
US5437994	Regents of The University of Michigan, Ann Arbor, MI, US	yes			A method for obtaining ex vivo human stem cell division comprising culturing a human hematopoie ic stem cell composition in a liquid culture medium and A method for culturing a human hematopoie ic progenitor cell composition comprising culturing human hematopoie ic progenitor cells in a liquid culture medium		hematopoietic progenitor cell	human		

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5453357	Vanderbilt University, Nashville, TN, US	yes		A composition comprising: (a) pluripotential embryonic stem cells; and (b) a fibroblast growth factor, leukemia inhibitory factor, membrane associated steel factor, and soluble steel factor in amounts to enhance the growth of and allow the continued prolifera ion of the cells.	A method of making a pluripotential embryonic stem cell	A method of screening cells which can be promoted to become pluripotent embryonic stem cells	pluripotent stem cells	embryonic		
US5460964	Regents of the University of Minnesota, Minneapolis, MN, US	yes			A cell culture method comprising culturing in vitro a population of human hematopoie ic cells comprising stem cells or committed progenitor cells		hematopoietic cells	human		
US5464753	Roninson; Igor B. Us	yes			A method of purifying a P- glycoprotein expressing pluripotent hematopoie ic stem cell from a mixture of blood or bone marrow cells		pluripotent hematopoietic stem cell	blood or bone marrow		

Patent Number	Assignee/Applica nt Name	In vitro	In vivo	Composition	Method of making	Use/Diagnostic use	Cell type	Tissue of origin	Therapy	Device
US5464764	University of Utah Research Foundation, Salt Lake City, UT, US	yes		negative selection (PNS) vector for modifying a target DNA sequence contained in the genomes of murine embryonic stem cells	transformed murine embryonic stem cell containing a modification in a		embryonic stem cell	murine		